Innovent Biologics (HK:1801) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Innovent Biologics has received approval from China’s National Medical Products Administration for its drug Dovbleron, a next-generation treatment for ROS1-positive non-small cell lung cancer. This marks the 13th addition to Innovent’s portfolio, highlighting the company’s commitment to innovative cancer therapies. The approval follows positive results from a pivotal Phase 2 trial, showcasing significant efficacy in patients.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.
